Chinese Sinovac is also developing a promising vaccine against Covid-19

Chinese Sinovac is also developing a promising vaccine against Covid-19
Chinese Sinovac is also developing a promising vaccine against Covid-19

Posted on Tuesday, December 8, 2020 at 1:28 p.m.

Through Sudinfo with Belga

Chinese company Sinovac has a vaccine against the coronavirus which, according to a spokesperson, created antibodies in 97% of subjects tested in Indonesia in a final phase of testing. However, the exact efficacy of the vaccine is yet to be determined.


Indonesian state-owned pharmaceutical company Bio Farma, which will distribute the vaccine in the domestic market, announced earlier today that the Chinese company’s vaccine has a 97% effectiveness. This would give it the greatest effectiveness of all the vaccines against the coronavirus developed so far.

Asked, the Sinovac spokesperson clarified that the exact effectiveness will not be determined until January. According to him, the 97% refers to the rate of seroconversion, which is not necessarily the same as that of efficacy.

Sinovac is also currently analyzing data from a phase 3 study in Brazil.

Unlike Western vaccine makers, the Chinese have yet to release the efficacy percentages of the tests in their final stages.

Source link
https://www.sudinfo.be/id292525/article/2020-12-08/le-chinois-sinovac-developpe-egalement-un-vaccin-prometteur-contre-le-covid-19

These were the details of the news Chinese Sinovac is also developing a promising vaccine against Covid-19 for this day. We hope that we have succeeded by giving you the full details and information. To follow all our news, you can subscribe to the alerts system or to one of our different systems to provide you with all that is new.

It is also worth noting that the original news has been published and is available at news1.news and the editorial team at AlKhaleej Today has confirmed it and it has been modified, and it may have been completely transferred or quoted from it and you can read and follow this news from its main source.